Lifecore Biomedical, Inc. (NASDAQ:LFCR) Holdings Decreased by Diametric Capital LP

Diametric Capital LP lessened its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 42.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,146 shares of the company’s stock after selling 32,379 shares during the period. Diametric Capital LP owned 0.12% of Lifecore Biomedical worth $321,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. DCF Advisers LLC boosted its holdings in shares of Lifecore Biomedical by 87.2% in the fourth quarter. DCF Advisers LLC now owns 539,989 shares of the company’s stock valued at $4,012,000 after acquiring an additional 251,511 shares in the last quarter. 272 Capital LP lifted its position in Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after purchasing an additional 120,002 shares during the period. Geode Capital Management LLC boosted its stake in Lifecore Biomedical by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock valued at $2,948,000 after purchasing an additional 55,703 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Lifecore Biomedical by 2,640.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after purchasing an additional 52,414 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Lifecore Biomedical in the 3rd quarter worth $207,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Insider Activity

In related news, CEO Paul Josephs purchased 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average price of $5.74 per share, with a total value of $97,580.00. Following the purchase, the chief executive officer now owns 559,717 shares of the company’s stock, valued at $3,212,775.58. This trade represents a 3.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 32.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an “equal weight” rating and set a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Lifecore Biomedical Stock Down 0.1 %

LFCR stock opened at $7.03 on Wednesday. The firm has a market cap of $260.29 million, a PE ratio of -12.55 and a beta of 0.96. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The firm has a 50 day simple moving average of $6.16 and a 200 day simple moving average of $6.23.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.